GlobeImmune sets terms for $60 million US IPO

By
A A A

GlobeImmune, a developer of therapeutic drugs for cancer and infectious diseases, announced terms for its IPO on Wednesday. The Louisville, CO-based company plans to raise $60 million by offering 5 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, GlobeImmune would command a market value of $207 million. GlobeImmune, which was founded in 1995 and booked $9 million in sales for the 12 months ended June 30, 2012, plans to list on the NASDAQ under the symbol GBIM. Wells Fargo Securities, Piper Jaffray, JMP Securities and Needham & Co. are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: GBIM

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

122,762,267
  • $15.81 ▼ 1.43%
62,277,320
  • $8.50 ▼ 6.80%
58,664,622
  • $128.46 ▼ 1.50%
48,473,163
  • $25.99 ▲ 0.39%
36,433,239
  • $5.12 ▲ 7.34%
35,593,669
  • $6.63 ▲ 5.41%
30,823,989
  • $16.68 ▼ 3.02%
30,676,302
    $2.08 unch
As of 2/27/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com